

Medigen Biotechnology Corp. (3176 MEDIGEN)

SEQ_NO	3	Date of announcement	2023/06/26	Time of announcement	17:43:26
Subject	2023 Annual Shareholders' Meeting has approved to remove the restrictions on non-competition for newly appointed independent director				
Date of events	2023/06/26	To which item it meets	paragraph 21		
Statement	<p>1. Date of the shareholders' meeting resolution: 2023/06/26</p> <p>2. Name and title of the managerial officer with permission to engage in competitive conduct: Lin, Sheue-Rong, Independent director</p> <p>3. Items of competitive conduct in which the officer is permitted to engage: The director is authorized to invest or to engage in business identical with the scope of the company's business.</p> <p>4. Period of permission to engage in the competitive conduct: During the tenure as an independent director of the Company</p> <p>5. Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act): The total number of votes were 83,614,474 and the voting result was: 82,876,163 in favor; 277,000 against; 461,311 abstentions; the resolution was passed with 99.11% of votes in favor.</p> <p>6. If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors (if it is not the operator of a mainland China enterprise, please enter "N/A" below): N/A</p> <p>7. Company name of the mainland China enterprise and the officer's position in the enterprise: N/A</p> <p>8. Address of the mainland China enterprise: N/A</p> <p>9. Operations of the mainland China enterprise: N/A</p> <p>10. Impact on the company's finance and business: N/A</p> <p>11. If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio: N/A</p> <p>12. Any other matters that need to be specified: None</p>				